Anti-VEGF Treatment Strategy for nAMD and DME Matters for Best Outcomes! Evaluating the Evidence
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
OVERVIEW
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC (PQHE), in collaboration with American Macular Degeneration Foundation (AMDF)
ACKNOWLEDGEMENT
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
DATE OF RELEASE/EXPIRATION
This activity was released on November 18, 2024, and is valid until November 18, 2025. Requests for credit must be made no later than November 18, 2025.
TARGET AUDIENCE
The educational design of this activity addresses the needs of ophthalmologists, retina specialists, and optometrists.
STATEMENT OF NEED/PROGRAM OVERVIEW
People with neovascular age-related macular degeneration (AMD) or diabetic macular edema (DME) have many barriers to optimal treatment, among them difficulty with managing frequent injection schedules and anxiety about eye injections. Join an expert panel of ophthalmologists to discuss burden of treatment for people with nAMD and DME and their caregivers, and review the clinical data on new anti-vascular endothelial growth factor (anti-VEGF) treatments and regimens. You will learn evidence-based strategies for selecting treatment and injection schedules, while reducing treatment frequency and burden, toward optimizing adherence and patient outcome.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Describe patient- and non-patient-related barriers that prevent people with nAMD from obtaining full benefit from standard treatment regimen with anti-VEGF therapies
- Review evidence on new anti-VEGF administration regimens and new agents to ensure durable vision gains and retinal-fluid reduction in nAMD
- Explain how integration of artificial intelligence could lead to earlier detection of nAMD
- Describe patient- and non-patient-related barriers that prevent people with DME from obtaining full benefit from standard treatment regimen with anti-VEGF therapies
- Review evidence on new anti-VEGF administration regimens and new agents to ensure durable vision gains and retinal-fluid reduction in DME
- Explain how integration of artificial intelligence could lead to earlier detection of DME
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETE
This activity should take approximately 45 minutes to complete.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
|
Name of Faculty or Presenter |
Reported Financial Relationship |
|
W. Lloyd Clark, MD Assistant Clinical Professor of Ophthalmology University of South Carolina School of Medicine |
Consulting Fee (e.g., Advisory Board): |
|
Jessica Randolph, MD Associate Professor Virginia Commonwealth University |
Consulting Fee (e.g., Advisory Board) |
|
Barbara Gilbert Patient with AMD Advocate for the Blind
|
Nothing to Disclose
|
The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support:
For any technical issues or issues with your CME Certificate, please contact Medlive at 877-394-1306 or at Support@Medlive.com.